Current Psychiatry Reports

, Volume 9, Issue 6, pp 467–474 | Cite as

The role of glutamate in mood disorders: Results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects

Article

Abstract

In this article, we first review a study showing that the N-methyl-d-aspartate (NMDA) receptor antagonist ketamine leads to rapid, robust, and relatively sustained antidepressant effects in patients with treatment-resistant major depression. We then discuss our hypothesis that the therapeutic effects of monoaminergic antidepressants and ketamine may be mediated by increased AMPA-to-NMDA glutamate receptor throughput in critical neuronal circuits. We hypothesize that ketamine directly mediates this throughput, whereas monoaminergic antidepressants work indirectly and gradually; this may explain, in part, the lag of onset of several weeks to months that is observed with traditional antidepressants.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Fagiolini A, Kupfer DJ, Masalehdan A, et al.: Functional impairment in the remission phase of bipolar disorder. Bipolar Disord 2005, 7:281–285.PubMedCrossRefGoogle Scholar
  2. 2.
    Huxley N, Baldessarini RJ: Disability and its treatment in bipolar disorder patients. Bipolar Disord 2007, 9:183–196.PubMedCrossRefGoogle Scholar
  3. 3.
    Rush AJ, Trivedi MH, Wisniewski SR, et al.: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163:1905–1917.PubMedCrossRefGoogle Scholar
  4. 4.
    Trivedi MH, Rush AJ, Wisniewski SR, et al.: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163:28–40.PubMedCrossRefGoogle Scholar
  5. 5.
    Manji HK, Moore GJ, Rajkowska G, Chen G: Neuroplasticity and cellular resilience in mood disorders. Mol Psychiatry 2000, 5:578–593.PubMedCrossRefGoogle Scholar
  6. 6.
    Payne JL, Quiroz JA, Zarate CA, Jr, Manji HK: Timing is everything: does the robust upregulation of norad-renergically regulated plasticity genes underlie the rapid antidepressant effects of sleep deprivation? Biol Psychiatry 2002, 52:921–926.PubMedCrossRefGoogle Scholar
  7. 7.
    Zarate CA, Jr, Singh J, Manji HK: Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry 2006, 59:1006–1020.PubMedCrossRefGoogle Scholar
  8. 8.
    Sanacora G, Rothman DL, Mason G, Krystal JH: Clinical studies implementing glutamate neurotransmission in mood disorders. Ann N Y Acad Sci 2003, 1003:292–308.PubMedCrossRefGoogle Scholar
  9. 9.
    Zarate CA, Jr, Du J, Quiroz J, et al.: Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann N Y Acad Sci 2003, 1003:273–291.PubMedCrossRefGoogle Scholar
  10. 10.
    Zarate CA, Quiroz J, Payne J, Manji HK: Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull 2002, 36:35–83.PubMedGoogle Scholar
  11. 11.
    Krystal JH, D’souza DC, Petrakis IL, et al.: NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry 1999, 7:125–143PubMedCrossRefGoogle Scholar
  12. 12.
    Manji HK, Quiroz JA, Sporn J, et al.: Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 2003, 53:707–742.PubMedCrossRefGoogle Scholar
  13. 13.
    Malinow R, Malenka RC: AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci 2002, 25:103–126.PubMedCrossRefGoogle Scholar
  14. 14.
    Zhu JJ, Qin Y, Zhao M, et al.: Ras and Rap control AMPA receptor trafficking during synaptic plasticity. Cell 2002, 110:443–455.PubMedCrossRefGoogle Scholar
  15. 15.
    Kim JS, Schmid-Burgk W, Claus D, Kornhuber HH: Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr 1982, 232:299–304.PubMedCrossRefGoogle Scholar
  16. 16.
    Altamura CA, Mauri MC, Ferrara A, et al.: Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 1993, 150:1731–1733.PubMedGoogle Scholar
  17. 17.
    Mauri MC, Ferrara A, Boscati L, et al.: Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 1998, 37:124–129.PubMedCrossRefGoogle Scholar
  18. 18.
    Mitani H, Shirayama Y, Yamada T, et al.: Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1155–1158.PubMedCrossRefGoogle Scholar
  19. 19.
    Frye MA, Tsai GE, Huggins T, et al.: Low cerebrospinal fluid glutamate and glycine in refractory affective disorder. Biol Psychiatry 2007, 61:162–166.PubMedCrossRefGoogle Scholar
  20. 20.
    Levine J, Panchalingam K, Rapoport A, et al.: Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry 2000, 47:586–593.PubMedCrossRefGoogle Scholar
  21. 21.
    Altamura C, Maes M, Dai J, Meltzer HY: Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur Neuropsychopharmacol 1995, 5(Suppl):71–75.PubMedCrossRefGoogle Scholar
  22. 22.
    Maes M, Verkerk R, Vandoolaeghe E, et al.: Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand 1998, 97:302–308.PubMedCrossRefGoogle Scholar
  23. 23.
    Maj J, Rogoz Z, Skuza G, Sowinska H: The effect of antidepressant drugs on the locomotor hyperactivity induced by MK-801, a non-competitive NMDA receptor antagonist. Neuropharmacology 1992, 31:685–691.PubMedCrossRefGoogle Scholar
  24. 24.
    Meloni D, Gambarana C, De Montis MG, et al.: Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats. Pharmacol Biochem Behav 1993, 46:423–426.PubMedCrossRefGoogle Scholar
  25. 25.
    Papp M, Moryl E: New evidence for the antidepressant activity of MK-801, a non-competitive antagonist of NMDA receptors. Pol J Pharmacol 1993, 45:549–553.PubMedGoogle Scholar
  26. 26.
    Skolnick P, Miller R, Young A, et al.: Chronic treatment with 1-aminocyclopropanecarboxylic acid desensitizes behavioral responses to compounds acting at the N-methyl-D-aspartate receptor complex. Psychopharmacology (Berl) 1992, 107:489–496.CrossRefGoogle Scholar
  27. 27.
    Trullas R, Folio T, Young A, et al.: 1-aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models. Eur J Pharmacol 1991, 203:379–385.PubMedCrossRefGoogle Scholar
  28. 28.
    Trullas R, Skolnick P: Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990, 185:1–10.PubMedCrossRefGoogle Scholar
  29. 29.
    Padovan CM, Guimaraes FS: Antidepressant-like effects of NMDA-receptor antagonist injected into the dorsal hippocampus of rats. Pharmacol Biochem Behav 2004, 77:15–19.PubMedCrossRefGoogle Scholar
  30. 30.
    Zarate CA, Jr, Payne JL, Quiroz J, et al.: An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004, 161:171–174.PubMedCrossRefGoogle Scholar
  31. 31.
    Zarate CA, Jr, Quiroz JA, Singh JB, et al.: An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005, 57:430–432.PubMedCrossRefGoogle Scholar
  32. 32.
    van Berckel BN, Lipsch C, Gispen-de Wied C, et al.: The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers. Psychopharmacology (Berl) 1998, 138:190–197.CrossRefGoogle Scholar
  33. 33.
    van Berckel BN, Lipsch C, Timp S, et al.: Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects. Neuropsychopharmacology 1997, 16:317–324.PubMedCrossRefGoogle Scholar
  34. 34.
    Lopes T, Neubauer P, Boje KM: Chronic administration of NMDA glycine partial agonists induces tolerance in the Porsolt swim test. Pharmacol Biochem Behav 1997, 58:1059–1064.PubMedCrossRefGoogle Scholar
  35. 35.
    Papp M, Moryl E: Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression. Eur J Pharmacol 1996, 316:145–151.PubMedCrossRefGoogle Scholar
  36. 36.
    Vamvakides A: D-cycloserine is active in the adult mouse and inactive in the aged mouse, in the forced swim test [in French]. Ann Pharm Fr 1998, 56:209–212.PubMedGoogle Scholar
  37. 37.
    Heresco-Levy U, Javitt DC, Gelfin Y, et al.: Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J Affect Disord 2006, 93:239–243.PubMedCrossRefGoogle Scholar
  38. 38.
    Reisberg B, Doody R, Stoffer A, et al.: Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003, 348:1333–1341.PubMedCrossRefGoogle Scholar
  39. 39.
    Zarate CA, Jr, Singh JB, Quiroz JA, et al.: A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006, 163:153–155.PubMedCrossRefGoogle Scholar
  40. 40.
    Bolshakov KV, Gmiro VE, Tikhonov DB, Magazanik LG: Determinants of trapping block of N-methyl-d-aspartate receptor channels. J Neurochem 2003, 87:56–65.PubMedCrossRefGoogle Scholar
  41. 41.
    Narita M, Yoshizawa K, Nomura M, et al.: Role of the NMDA receptor subunit in the expression of the discriminative stimulus effect induced by ketamine. Eur J Pharmacol 2001, 423:41–46.PubMedCrossRefGoogle Scholar
  42. 42.
    De Vry J, Jentzsch KR: Role of the NMDA receptor NR2B subunit in the discriminative stimulus effects of ketamine. Behav Pharmacol 2003, 14:229–235.PubMedGoogle Scholar
  43. 43.
    Maler JM, Esselmann H, Wiltfang J, et al.: Memantine inhibits ethanol-induced NMDA receptor up-regulation in rat hippocampal neurons. Brain Res 2005, 1052:156–162.PubMedCrossRefGoogle Scholar
  44. 44.
    Green SM, Rothrock SG, Harris T, et al.: Intravenous ketamine for pediatric sedation in the emergency department: safety profile with 156 cases. Acad Emerg Med 1998, 5:971–976.PubMedGoogle Scholar
  45. 45.
    Berman RM, Cappiello A, Anand A, et al.: Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351–354.PubMedCrossRefGoogle Scholar
  46. 46.
    Zarate CA, Jr, Singh JB, Carlson PJ, et al.: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63:856–864.PubMedCrossRefGoogle Scholar
  47. 47.
    Entsuah AR, Huang H, Thase ME: Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 2001, 62:869–877.PubMedCrossRefGoogle Scholar
  48. 48.
    Thase ME, Haight BR, Richard N, et al.: Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry 2005, 66:974–981.PubMedGoogle Scholar
  49. 49.
    Wirz-Justice A, Van den Hoofdakker RH: Sleep deprivation in depression: what do we know, where do we go? Biol Psychiatry 1999, 46:445–453.PubMedCrossRefGoogle Scholar
  50. 50.
    Husain MM, Rush AJ, Fink M, et al.: Speed of response and remission in major depressive disorder with acute electroconvulsive therapy (ECT): a Consortium for Research in ECT (CORE) report. J Clin Psychiatry 2004, 65:485–491.PubMedCrossRefGoogle Scholar
  51. 51.
    Marangell LB, George MS, Callahan AM, et al.: Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients. Arch Gen Psychiatry 1997, 54:214–222.PubMedGoogle Scholar
  52. 52.
    DeBattista C, Posener JA, Kalehzan BM, Schatzberg AF: Acute antidepressant effects of intravenous hydrocortisone and CRH in depressed patients: a double-blind, placebocontrolled study. Am J Psychiatry 2000, 157:1334–1337.PubMedCrossRefGoogle Scholar
  53. 53.
    Krystal JH, Karper LP, Seibyl JP, et al.: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994, 51:199–214.PubMedGoogle Scholar
  54. 54.
    Moghaddam B, Adams B, Verma A, Daly D: Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997, 17:2921–2927.PubMedGoogle Scholar
  55. 55.
    Maeng S, Zarate CA, Jr, Du J, et al.: Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2007 [Epub ahead of print].Google Scholar
  56. 56.
    Du J, Suzuki K, Wei Y, et al.: The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 2007, 32:793–802.PubMedCrossRefGoogle Scholar
  57. 57.
    Li X, Tizzano JP, Griffey K, et al.: Antidepressant-like actions of an AMPA receptor potentiator (LY392098). Neuropharmacology 2001, 40:1028–1033.PubMedCrossRefGoogle Scholar
  58. 58.
    Zarate CA, Jr, Charney DS, Manji HK: Searching for rational anti-N-methyl-D-aspartate treatment for depression. Arch Gen Psychiatry 2007, 64:1100–1101.CrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.10 Center DriveCRCBethesdaUSA

Personalised recommendations